ArticleBMC cancer2011
Prognostic impact of CD168 expression in gastric cancer.
Article in BMC cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 50 citations in OpenAlex.
- CD168 in lung adenocarcinoma: prognostic relevance, immune feature associations, and MAPK/ERK pathway enrichment.Medical oncology (Northwood, London, England) · 2026Article
- Hyaluronan-Mediated Motility Receptor (HMMR) Overexpression Is Correlated with Poor Survival in Patients with B-ALL.International journal of molecular sciences · 2025Article
- miR-9-5p/HMMR regulates the tumorigenesis and progression of clear cell renal cell carcinoma through EMT and JAK1/STAT1 signaling pathway.Journal of translational medicine · 2025Article
- CMTM6 as a potential therapy target is associated with immunological tumor microenvironment and can promote migration and invasion in pancreatic adenocarcinoma.Functional & integrative genomics · 2023Article
- Increased expression of HMMR in renal cell carcinoma is an independent prognostic factor.Oncology letters · 2023Article
- CMTM6, a potential immunotherapy target.Journal of cancer research and clinical oncology · 2022Review
- The Impact of Hyaluronic Acid on Tendon Physiology and Its Clinical Application in Tendinopathies.Cells · 2021Review
- Hyaluronan-mediated motility receptor expression functions as a prognostic biomarker in uterine carcinosarcoma based on bioinformatics analysis.The Journal of international medical research · 2021Article
- Identification of the HMMR Gene as a Diagnostic and Prognostic Biomarker in Hepatocellular Carcinoma Based on Integrated Bioinformatics Analysis.Evidence-based complementary and alternative medicine : eCAM · 2021Article
- Establishment of a Gene Signature to Predict Prognosis for Patients with Lung Adenocarcinoma.International journal of molecular sciences · 2020Article
- Identification of the association between HMMR expression and progression of hepatocellular carcinoma via construction of a co-expression network.Oncology letters · 2020Article
- SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.BMC medical genomics · 2020Article
- Role of extra cellular proteins in gastric cancer progression and metastasis: an update.Genes and environment : the official journal of the Japanese Environmental Mutagen Society · 2020Review
- Review
- Article
- Integrated analysis reveals key genes with prognostic value in lung adenocarcinoma.Cancer management and research · 2018Article
- Genetic Alterations in Gastric Cancer Associated withFrontiers in medicine · 2017Review
- Hyaluronic acid in digestive cancers.Journal of cancer research and clinical oncology · 2017Review
- The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells.Oncotarget · 2016Article
- Prognostic significance of CD168 overexpression in colorectal cancer.Oncology letters · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInteractions of stromal hyaluronic acid (HA) with its binding protein RHAMM (receptor for HA-mediated motility) (CD168) have been reported to affect tumor extension and the migration of crucial molecules to promote tumor progression and metastases. Cancerous CD168 expression is correlated with aggressive biological features in several cancers. However, the clinical implications of CD168 positivity in gastric cancer have remained unclear.
methodsWe examined the CD168 expression of 196 consecutive gastric cancer patients by immunohistochemistry. According to CD168 positivity, the 196 gastric cancer patients were divided into two groups (57 CD168-positive and 139 CD168-negative patients). The correlation between CD168 expression and clinicopathological factors (age, sex, histology, tumor depth, lymph node status, and vessel invasion) was evaluated according to the Japanese Classification of Gastric Carcinoma.
resultsCancerous CD168 expression was detectable in 57 of the 196 tumors (29%). CD168 positivity was significantly correlated with the depth of invasion, nodal involvement, and vessel invasion (p < 0.01). Survival analysis of the 196 gastric cancer patients showed that the CD168-positive group had a significantly higher mortality than the CD168-negative group (p < 0.01). In terms of a correlation with CD168 positivity at separate clinical stages, a significance difference was only found in stages II and III. Multivariate analysis revealed that CD168 expression was a significant independent prognostic marker (p = 0.013) after depth of invasion (p < 0.005) and nodal involvement (p < 0.01).
conclusionOur results suggest that cancerous CD168 positivity is strongly related to the invasion and metastasis of gastric cancer tumors. These results suggest that cancerous CD168 expression can be used as a prognostic marker of gastric cancer owing to its interactions with stromal hyaluronic acid.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.